Cargando…

Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists

Detalles Bibliográficos
Autores principales:	van Heteren, D. Max, Lijfering, Willem M., van der Meer, Felix J. M., Reitsma, Pieter H., Swen, Jesse J., Bos, Mettine H. A., van Rein, Nienke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087804/ https://www.ncbi.nlm.nih.gov/pubmed/36125842 http://dx.doi.org/10.1111/joim.13569

Ejemplares similares

Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
por: Bakker, Sanne, et al.
Publicado: (2022)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk
por: Reitsma, Pieter H, et al.
Publicado: (2005)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Factor V levels and risk of venous thrombosis: The MEGA case‐control study
por: Rietveld, Inge M., et al.
Publicado: (2018)

Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding
por: Schreuder, Mark, et al.
Publicado: (2019)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Lipid levels and risk of venous thrombosis: results from the MEGA-study
por: Morelli, Vânia M., et al.
Publicado: (2017)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2022)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

VKORC1 and VKORC1L1: Why do Vertebrates Have Two Vitamin K 2,3-Epoxide Reductases?
por: Oldenburg, Johannes, et al.
Publicado: (2015)

Platelet Dysfunction in Thrombosis Patients Treated with Vitamin K Antagonists and Recurrent Bleeding
por: van der Meijden, Paola E. J., et al.
Publicado: (2013)

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial
por: Orsi, Fernanda A., et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

ptFVa (Pseudonaja Textilis Venom-Derived Factor Va) Retains Structural Integrity Following Proteolysis by Activated Protein C
por: Schreuder, Mark, et al.
Publicado: (2021)

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study
por: Toorop, Myrthe M. A., et al.
Publicado: (2021)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda D., et al.
Publicado: (2021)

Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial
por: Camilleri, Eleonora, et al.
Publicado: (2023)

New insights into the catalytic mechanism of vitamin K epoxide reductase (VKORC1) – The catalytic properties of the major mutations of rVKORC1 explain the biological cost associated to mutations()
por: Matagrin, Benjamin, et al.
Publicado: (2013)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Vitamin K epoxide reductase complex subunit 1 (Vkorc1) haplotype diversity in mouse priority strains
por: Song, Ying, et al.
Publicado: (2008)

Vitamin K antagonist use and renal function in pre-dialysis patients
por: Voskamp, Pauline WM, et al.
Publicado: (2018)

Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease
por: Kooiman, Judith, et al.
Publicado: (2014)

VKORC1L1, An Enzyme Mediating the Effect of Vitamin K in Liver and Extrahepatic Tissues
por: Lacombe, Julie, et al.
Publicado: (2018)

Genetic Polymorphism of VKORC1-1639 in Children With Intracranial Hemorrhage Due to Vitamin K Deficiency
por: Berber, Uğur, et al.
Publicado: (2018)

Distribution of anticoagulant rodenticide resistance in Rattus norvegicus in the Netherlands according to Vkorc1 mutations
por: Meerburg, Bastiaan G, et al.
Publicado: (2014)

Variation in VKORC1 Is Associated with Vascular Dementia
por: Mur, Jure, et al.
Publicado: (2021)

Risk of drug-related upper gastrointestinal bleeding in the total population of the Netherlands: a time-trend analysis
por: Bedene, Ajda, et al.
Publicado: (2022)

VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation
por: Marinova, Milka, et al.
Publicado: (2012)

Establishment of the Variation of Vitamin K Status According to Vkorc1 Point Mutations Using Rat Models
por: Debaux, Jean Valéry, et al.
Publicado: (2019)

Direct oral anticoagulant use and risk of perioperative bleeding: Evidence of absence or absence of evidence?
por: Lijfering, Willem M., et al.
Publicado: (2018)

Large‐scale identification of rodenticide resistance in Rattus norvegicus and Mus musculus in the Netherlands based on Vkorc1 codon 139 mutations
por: Krijger, Inge M., et al.
Publicado: (2022)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Structural Modeling Insights into Human VKORC1 Phenotypes
por: Czogalla, Katrin J., et al.
Publicado: (2015)

GGCX and VKORC1 inhibit osteocalcin endocrine functions
por: Ferron, Mathieu, et al.
Publicado: (2015)

Comparative Risk of Bleeding of Anticoagulant Therapy with Vitamin K Antagonists (VKAs) and with Non-Vitamin K Antagonists in Patients Undergoing Dental Surgery
por: Manfredini, Mattia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_svu1b5h54483kgrg6qg927q1qn